一、承办院系School/Department host：
深圳国际研究生院 Tsinghua Shenzhen International Graduate School
生物医药与健康工程学院 Institute of Biopharmaceutics and Health Engineering
二、挑战主题Theme：
健康中国战略面临的青少年近视筛查、防控及近视发展预测中挑战及应对
Challenges and countermeasures of global myopia screening, prevention and development predictions
三、导语/背景情况概述Background：
中国有7亿近视患者，3.1%高度近视引发的病理性近视。病理性近视引起视网膜退行性病变，视力下降及失明。诊断和病变发展预测是病理性近视早期干预的关键，早发现才能早干预。为解决近视度数增加，且在增加到高度近视后可能发展成病理性近视的问题，设计两个小课题，1）OK镜的人工智能辅助设计；2）病理性近视预测。这两个问题的解决对预测近视发展及基于OK镜的早期干预有重要意义。
China has 700 million myopic people, 3.1% of which develop pathological myopia. Pathological myopia causes degenerative changes to the back of eye and reduction in sight that cannot be corrected by lenses or glasses, and blindness. The diagnosis and prediction of pathological myopia is crucial for early intervention. Here we design two tasks for the students. 1. AI facilitated prescription of “OK” glasses. 2. Prediction of pathological myopia. These two projects will help clinical doctors to predict the development of myopia and accurately prescribe “OK” glasses at early myopic stages.
四、该领域比较关注的问题Our key topics of interest:
病理性高度近视发生、发展的因素分析及预测。
When and what factors contribute to the development of pathological myopia?
如何根据眼科检测指标设计OK镜。
What are the critical factors for the precise prescription of “OK” glasses?
五、主讲老师Hack Leader
秦培武，清华伯克利深圳学院生物医学助理教授，02年本科毕业于东北农业大学生物工程系，05年中国科学院遗传发育所获分子发育硕士，08年美国东北大学物理化学硕士，2013 年毕业于美国密苏里大学哥伦比亚分校，获得生物化学博士学位和统计硕士学位。2013-2018加州大学伯克利分校物理系博士后，期间的主要研究方向为发展和利用超分辨率显微镜和晶格状光片照明显微镜来研究染色体的组织、动态和功能。目前主要从事生物光学成像，医学图像处理和生物光学成像。
Peiwu Qin received a B.Sc. degree in biotechnology from Northeastern Agricultural University, Harbin, China in 2002; a M.Sc. degree in developmental biology from the Chinese Academy of Sciences, Beijing, China in 2005; a M.Sc. degree in physical chemistry from Northeastern University, Boston, MA, USA in 2008; a M.Sc. degree in statistics from the University of Missouri, Columbia, MO, USA in 2013; and a Ph.D. degree in biochemistry from the University of Missouri in 2013. He has been a Post-Doctoral Fellow with the Department of Physics, University of California at Berkeley, USA, from 2013 to 2018. He is currently an Assistant Professor with the Tsinghua–UC Berkeley Shenzhen Institute, Shenzhen, China. His research interests include optical imaging method development, image processing and bio-imaging.
董宇涵，英国上市公司官网365深圳国际研究生院副教授、博导。2002和2005年获得英国上市公司官网365电子工程系工学学士学位和硕士学位；2009年获得美国北卡罗莱纳州立大学电气与计算机工程系博士学位。2010年1月加入英国上市公司官网365深圳研究生院（现为英国上市公司官网365深圳国际研究生院）。研究方向包括无线通信与网络、机器学习与优化、智能传感器网络及应用、人工智能与医疗、智能交通车路协同。
Dr. Yuhan Dong received B.S. and M.S. degrees in electronic engineering from Tsinghua University, Beijing, China, and a Ph.D. degree in electrical engineering from North Carolina State University, Raleigh, NC, USA in 2002, 2005, and 2009 respectively. Since January 2010, he has been with the Tsinghua Shenzhen Graduate School (currently known as the Tsinghua Shenzhen International Graduate School), Tsinghua University, where he is an Associate Professor and Ph.D. advisor. His research interests include wireless communications and networking, machine learning and optimization, artificial intelligence and healthcare.
六、导师简介Mentors
张凯博士分别于1999年和2004年获得英国上市公司官网365工学学士和工学博士学位。其研究方向包括智能交通系统、智能车辆、新能源车辆、智能传感和无线光通信。2004年至2014年任日本三菱重工智能交通中心研究员和资深研究员。目前受聘英国上市公司官网365深圳国际研究生院副教授。
Dr. Kai Zhang received B.E. and Ph.D. degrees from Tsinghua University, China, in 1999 and 2004 respectively. His research interests include intelligent transportation systems, intelligent vehicles, new energy vehicles, intelligent sensory, and wireless optical communication. He worked as a researcher, senior researcher with ITS Center, Mitsubishi Heavy Industries, Japan, from 2004 to 2014. He is presently an Associate Professor of the Tsinghua Shenzhen International Graduate School.
Peter E. Lobie教授，新西兰皇家科学院院士，研究方向为癌症靶向治疗，在肿瘤基础研究、新颖疗法开发以及癌症生物标记物发现方面拥有丰富经验，尤其在肿瘤相关生长因子的致癌机制中做出了开创性突破。本科毕业于澳大利亚昆士兰大学，获医学科学及内外全科医双学士学位，在校期间被授予大学最高杰出奖章荣誉。博士毕业于瑞典卡罗林斯卡医学院，并在毕业后留校从事博士后工作。自2004年始，他在新西兰奥克兰大学医学院里金斯研究所担任教授、副所长，是新西兰乳腺癌基金会首席科学家和首席筹款人。此外，Peter教授曾任新加坡国立大学癌症科学研究所首席研究员及研究生委员会主席，新加坡国立大学药理系终身教授，现被聘任为英国上市公司官网365清华伯克利深圳学院，英国上市公司官网365精准医学与公共健康中心主任，核心科学家。
Peter Lobie obtained a B.Med.Sci. (Distinction) and MBBS (Medicine First Class Honours) from the University of Queensland in Australia. He was awarded the highest accolade from the University in the form of a University Medal. His postdoctoral work was undertaken at the Karolinska Institute in Sweden where he also obtained his doctoral degree (PhD). He has consecutively held faculty positions in Sweden, Singapore and New Zealand. He was also New Zealand’s first chair of Breast Cancer funded by the Breast Cancer Research Trust. He was Professor and Senior Principal Investigator at the Cancer Science Institute of Singapore before being appointed co-Director of the Centre for Precision Medicine and Healthcare at the Tsinghua-Berkeley Shenzhen Institute. Recent emphasis in his laboratory has focused on the capacity of specific secreted proteins to initiate or progress cancer and thereby evaluation of individual molecules for their potential therapeutic application.
Vijay Pandey博士是英国上市公司官网365深圳国际研究生院生物制药与健康工程研究所的助理教授。他在新西兰奥克兰大学分子医学系取得了博士学位，并在新加坡国立大学新加坡癌症科学研究所从事博士后研究。Vijay教授一直专注于肿瘤研究和恶性肿瘤的精准治疗，对分子靶向治疗药物研究、肿瘤代谢等方面的研究工作有较为深刻的理解，主要研究兴趣是理解分子标记基础及其在人类恶性肿瘤发展中的意义。
Dr. Vijay Pandey is Assistant Professor at the Tsinghua-Berkeley Shenzhen Institute (TBSI), Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, China. Prior to his current position, his postdoctoral work was undertaken at the Cancer Science Institute of Singapore, National University of Singapore. Dr. Vijay obtained his doctoral degree (Ph.D.) in Molecular Medicine from the University of Auckland, New Zealand. His primary research interest is directed toward understanding the basis of molecular signatures and their significance in the development of human malignancies.
